

Breakeven Point Analysis on Rotavirus Vaccination in the National Immunization Program: A Summary from an Indochina Country

Dear Editor,

Rotavirus infection is an important infection in pediatrics. At present, vaccine is available for prevention of this viral infection. In some countries, due to the high prevalence of rotavirus infection, the rotavirus vaccination is already included into the national immunization program. The good examples of country that the rotavirus vaccination is considered for inclusion into the national immunization program are Bhutan and Thailand.^[1,2] Regarding Thailand, rotavirus vaccination is already included at present. As a new vaccine in this setting, there are some reports on medial economic analysis on rotavirus vaccines.^[2,3] In this setting, it is approved that the vaccine is cost-effective than no vaccination.

Nevertheless, an important consideration in implementation of national policies is on the budgeting. There is a need for additional analysis to determine breakeven point of the investment. In this report, the authors retrospectively analyze on the available data^[2,3] to estimate the breakeven point of the rotavirus vaccination program. Conceptually, breakeven point is the point that the investment is equal to gain. From the analysis, within the 5 years, the net expenditure for investment is equal to 8.50–9.36 million USD or 1.70–1.87 USD per year and the gain per year is equal to 13–33 million USD. Based on this data, it can show that the vaccination can reach breakeven point within its first year of implementation. It can show that rotavirus vaccination is useful and medical economic considerable and appropriate preventive medicine policies.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

**Rujittika Mungmunpantipantip,
Viroj Wiwanitkit¹**

Private Academic Consultant, Bangkok, Thailand, ¹Department of Community Medicine Dr DY Patil University, Pune, India

Address for correspondence:

Dr. Rujittika Mungmunpantipantip,

Private Academic Consultant, 26 Bangkok 11, Bangkok 103300 Thailand.

E-mail: rujittika@gmail.com

Received: 06 Feb 21 **Accepted:** 24 May 21

Published: 24 May 23

References

1. Pempa, Luz ACG, Luangasanatip N, Kingkaew P, Adhikari D, Isaranuwatthai W, *et al.* Economic evaluation of rotavirus vaccination in children of Bhutan. *Vaccine* 2020;38:5049-59.
2. Saokaew S, Prasitsuebsai W, Bibera GL, Kengkla K, Zhang XH, Oh KB, *et al.* Economic evaluation of human rotavirus vaccine in Thailand. *Infect Dis Ther* 2019;8:397-415.
3. Luangasanatip N, Mahikul W, Poovorawan K, Cooper BS, Lubell Y, White LJ, *et al.* Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand. *Vaccine* 2021;39:1402-14.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online

Quick Response Code:



Website:

www.ijpvmjournal.net/www.ijpvm.ir

DOI:

10.4103/ijpvm.ijpvm_43_21

How to cite this article: Mungmunpantipantip R, Wiwanitkit V. Breakeven point analysis on rotavirus vaccination in the national immunization program: A summary from an indochina country. *Int J Prev Med* 2023;14:57.

© 2023 International Journal of Preventive Medicine | Published by Wolters Kluwer - Medknow